Details of the Drug Combination

General Information of Drug Combination (ID: DC2EEYD)

Drug Combination Name
Lanreotide acetate Cabozantinib
Indication
Disease Entry Status REF
Metastatic Well Differentiated Neuroendocrine Neoplasm Phase 2 [1]
Component Drugs Lanreotide acetate   DMG6ZU4 Cabozantinib   DMIYDT4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lanreotide acetate
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Approved [2]
Lanreotide acetate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Somatostatin receptor type 2 (SSTR2) TTZ6T9E SSR2_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of Cabozantinib
Disease Entry ICD 11 Status REF
Medullary thyroid gland carcinoma N.A. Approved [3]
Thyroid cancer 2D10 Approved [4]
Ovarian cancer 2C73 Phase 2 [4]
Cabozantinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Inhibitor [5]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Cabozantinib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Cabozantinib Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Phosphorylation [8]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04427787) A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
2 Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
3 Cabozantinib FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
5 Clinical pipeline report, company report or official report of Exelixis (2011).
6 Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064.
7 FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration.
8 ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
9 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.